血管内皮生长因子在糖尿病大鼠视网膜中的表达

目的 :利用糖尿病大鼠动物模型 ,通过大鼠视网膜中血管内皮生长因子 ( vascular en-dothelial growth factor,VEGF)的表达情况 ,探讨 VEGF在糖尿病视网膜病变 ( diabetic retinopa-thy,DR)发展过程中作用机理。方法 :复制链脲佐菌素 ( streptozocin,STZ)糖尿病大鼠动物模型 ,取不同组、不同时期大鼠视网膜 ,利用免疫组织化学及原位杂交方法 ,检测 VEGF蛋白质及 m RNA的表达情况。结果 :1正常对照组 ( M)、血糖恢复组及糖尿病 1个月组 ( M1)大鼠视网膜均无 VEGF蛋白质及 m RNA的阳性表达 ;2糖尿病 3个月组 ( M3 )未见 VEGF m RNA表达 ,而在内核层及节细胞层有 VEGF蛋白表达阳性 ( 34%) ,此表达与胶质纤维酸性蛋白 ( GFAP)染色阳性细胞相同 ;3糖尿病 5个月组 ( M5) VEGF m RNA表达阳性率为 67%,表达位于视网膜各层 ,内界膜中的表达与 GFAP免疫组化阳性分布相同 ,VEGF蛋白质表达强阳性 ( 89%) ,主要位于内核层、节细胞层的细胞及血管上。结论 :VEGF在 STZ大鼠视网膜中的表达与病程相关 ,而且 VEGF的产生存在着自分泌和旁分泌多种途径     

腺病毒介导的TGF-β1基因转导对小鼠自身免疫性心肌炎的治疗作用

目的:研究腺病毒介导的TGF-β1基因转导对小鼠自身免疫性心肌炎的治疗作用.方法:以猪心肌肌凝蛋白免疫BALB/c小鼠,诱导自身免疫性心肌炎;实验组以腺病毒为载体转移TGF-β1基因,对照组则转移Lacz基因;采用ELISA法测定血浆TGF-β1浓度,间接ELISA法检测肌凝蛋白自身抗体,荧光酶联免疫法检测肌钙蛋白I;从心肌炎细胞浸润程度、血浆肌钙蛋白I水平、血浆肌凝蛋白自身抗体滴度评估TGF-β1转基因治疗自身免疫性心肌炎的作用.结果:实验组血浆TGF-β1浓度显著高于对照组和正常小鼠(P<0.01),对照组和正常小鼠无显著性差异;实验组小鼠心肌炎细胞浸润程度明显低于对照组,血浆中的肌钙蛋白I水平和抗肌凝蛋白自身抗体水平低于对照组(P<0.01).结论:腺病毒介导的TGF-β1基因转导对小鼠自身免疫性心肌炎有明显的治疗效果.     

胰腺癌细胞的增殖同膜脂质饱和度,膜胰岛素受体的关系

外源性表皮生长因子(或生长抑素)能促进(或抑制)胰腺癌细胞的增殖。胰腺癌细胞增殖速率的高低与细胞膜脂质饱和度的降、升;与膜胰岛素受体数量的增减密切相关。测定细胞膜脂质饱和度和胰岛素受体数量,是判断胰腺癌增殖状态的灵敏指标,有一定临床价值。     

Therapeutic effects of liposomal adriamycin in combination with tumor necrosis factor-alpha.

Liposomes as drug carriers in cancer chemotherapy have attracted considerable interest. To enhance the therapeutic effect of Adriamycin entrapped in liposomes (Lip-ADM) on human solid tumors, we investigated the therapeutic effects of Lip-ADM in combination with recombinant human tumor necrosis factor-alpha (rTNF-alpha), which is known to have specific effects on tumor vasculature. rTNF-alpha or saline solution was injected intravenously into nude mice bearing a human colon cancer strain, HC-1, at 1 hour before intravenous administration of Lip-ADM. The significant therapeutic effect of Lip-ADM in combination with rTNF-alpha was demonstrated by the evaluation with tumor growth curve and the actual tumor weights, in comparison with groups of mice treated with saline solution, rTNF-alpha alone, or with a Lip-ADM after saline. Levels of Adriamycin in tumor tissue in the Lip-ADM in combination with rTNF-alpha-treated group were higher than those in Lip-ADM with saline solution-treated group.     

重组人生长激素对内毒素血症大鼠的治疗作用

目的 :观察重组人生长激素 (rhGH)对大鼠内毒素血症的治疗效果。方法 :76只SD大鼠随机分为正常对照组、内毒素血症组 (仅腹腔注射鸵鸟株大肠杆菌 (1 5ml/kg ,1× 1 0 10 cfu/L)及治疗组 (腹腔注射鸵鸟株大肠杆菌后行rhGH肌肉注射 (2 2 5IU/kg/d)。内毒素血症组及治疗组又依观察时点再分为 1天、3天两个亚组。采用放射免疫分析方法测定血浆肿瘤坏死因子 α(TNF α)浓度并观测大鼠血压的变化。结果 :与正常对照组相比 ,无论是内毒素血症组还是治疗组 ,1天时其大鼠血浆TNF α浓度均明显升高 (P <0 .0 5 ) ;虽然两组大鼠血压都降低 (P <0 .0 5 ) ,但治疗组大鼠血压降低幅度明显小于内毒素血症组 (P <0 .0 0 1 )。 3天时 ,内毒素血症组大鼠血浆TNF α浓度降至正常对照水平 ,而治疗组大鼠血浆TNF α浓度却明显低于正常对照组 (P <0 .0 0 1 )及内毒素血症组 3天水平 (P <0 .0 5 )。结论 :rhGH能明显减轻内毒素血症大鼠血压的下降 ,对内毒素血症大鼠具有较理想的治疗效果 ;rhGH减轻血压下降的机制可能与其能抑制TNF的释放等有关     

Postnatal development of the hamster coclea. I. Growth of hair cells and the organ of Corti

A morphometric analysis of the developing organ of Corti and its component hair cells was carried out in an age-graded series of Syrian golden hamsters with the aid of scanning electron microscopy. The purpose was to establish a quantitative framework that would provide insight into the rules and principles by which the mammalian cochlea attains its adult proportions. This study examined postnatal development at two day intervals from birth to 22 days after birth. Our analysis included measures of cochlear length and hair cell numbers as well as measures of hair cell sizes in each of five sectors along the cochlear spiral. Our results demonstrate several principles of cochlear development: (1) The full two and one-fourths turns seen in the adult cochlea are already present at birth, but the cochlea continues to elongate for the next 10–12 days. (2) Development of hair cells in the apex generally lags behind that in the base. Whereas the stereocilia and apical margins of hair cells are clearly defined in the basal turn, they become well defined in the apex only postnatally. (3) Growth in cochlear length occurs mainly by increases in cell size rather than in cell numbers; although hair cells do increase in numbers during the first 4 days of cochlear growth, this increase involves addition of hair cells only to preexisting regions of the cochlear apex. Moreover, the full complement of hair cells is established 6 days before the full size of the cochlea is attained; in contrast, hair cell growth occurs at all positions along the cochlear spiral and spans the entire period of cochlear elongation. (4) The period of hair cell growth exceeds the period of organ of Corti growth and appears to be possible by decreases in intercellular spacing, primarily in the apical region of the cochlea; inner and outer hair cell growth was complete between 16 and 18 days after birth. (5) Inner and outer hair cell neighbors remain virtually constant at different ages indicating that the spatial relationships between the two hair cell populations is preserved as the cochlea grows. (6) Comparison with previous developmental studies of auditory function in the hamster reveals that the age of 16 days after birth, when hair cells attain their mature sizes, coincides with the onset of brainstem auditory evoked responses. Growth of hair cell somas alone, however, cannot explain either the subsequent maturation of evoked potential thresholds or changes in frequency representation in the developing cochlea. © Wiley-Liss, Inc.     

Expression of IGF-I and IGF-II mRNA in breast tissue

Summary Expression of IGF-I and IGF-II was studied in human breast cancer tissues by in situ hybridization. IGF-I mRNA was detected only in stromal cells adjacent to normal breast epithelial cells. Stromal cells associated with the tumor cells did not contain IGF-I, nor did malignant or benign breast epithelial cells. In contrast, IGF-II mRNA was found in both the malignant epithelial cells and their adjacent stromal cells. These data imply that stromal cells associated with breast epithelium may switch expression from IGF-I to IGF-II during breast cancer evolution. This appearance of IGF-II expression may identify cancer-associated stromal cells that have a fetal phenotype.     

Gln与rhGh对肝硬化病人肠黏膜屏障的影响

目的观察Gln与rhGh各单独应用及联合应用对肝硬化病人小肠黏膜屏障形态学和功能学的影响。方法20个肝硬化病人随机分成四组,给予等氮等热量营养支持7d,Gln+rhGh组口服Gln[0.3g/(Kg·d)]和皮下注射rhGh(10U/d);Gln组口服Gln;rhGh组应用皮下注射rhGh;CONT对照组应用相应安慰剂。观察治疗前后患者小肠黏膜通透性和十二指肠黏膜绒毛高度和隐窝深度的变化,分别比较。结果Gln+rhGh组治疗后小肠黏膜通透性有显著性的降低(P<0.05),且显著低于其他三组(P<0.05);十二指肠黏膜绒毛高度和隐窝深度有显著性的增高(P<0.05),且显著高于其他三组(P<0.05)。结论Gln与rhGh联合应用能减低肠道黏膜的通透性和维持其形态学的完整。     

VEGF-C和VEGF-D蛋白表达在胰腺癌淋巴转移中的意义

目的探讨胰腺癌中VEGF-C、VEGF-D蛋白表达与淋巴结转移之间的相关关系,阐明癌周淋巴管增生在胰腺癌淋巴转移中的作用及意义。方法免疫组化检测30例胰腺癌组织中VEGF-C、VEGF-D的表达及其与临床病理、淋巴结转移的关系。结果胰腺癌VEGF-C、VEGF-D蛋白表达阳性率分别为73%(22/30)、57%(17/30),肿瘤周边部位显著高于肿瘤中心部位,其表达与肿瘤的部位、分化程度、组织学类型无关,与肿瘤的TNM分期有关,Ⅲ~Ⅳ期显著高于Ⅰ~Ⅱ期。在VEGF-C、VEGF-D蛋白阳性组,淋巴结转移均显著增多。结论VEGF-C和VEGF-D与诱导胰腺癌淋巴管生成,促进肿瘤细胞淋巴道转移有关。     

BIOEQUIVALENCE BETWEEN rhGH FOR RECONSTITUTION AND READY-TO-USE rhGH IN TWO LIQUID FORMULATIONS

Objective To evaluate the bioequivalence between recombinant human growth hormone （rhGH） for reconstitution, and two dosages of liquid formulation of rhGH [ （151U） 5mg or （301U） lOmg per 3ml ]. Methods The study drugs were tested in a randomized, single-blind and three-period crossover studies in 24 healthy male subjects. The three drugs were administered by subcutaneous injection at a dose of O. 21U/kg body weight. A continuous somatostatin infusion was given in order to suppress the secretion of endogenous GH. The ve- nous blood samples were drawn at different time points to test the serum concentration of GH. The pharmacokinetic parameters were analyzed by statistical methods. Results 90% confidence intervals （CI） of AUC0-24h among three products were all within 80% - 125% interval （ 103. 4% - 116. 5%, 105. 7% - 119. 6% and 91.9% - 103. 7%, respectively）, and the Cls of C,~ among three products were all within 70% - 143% interval （91.9% - 114. 0%, 103. 7% -127. 2% and 81.6% -97. 4%, respectively）. There was no statisitical difference of tmax among all the three products. Conclusion These data demonstrate that there is bioequivalence between rhGH for reconstitution and two liquid formulations of rhGH.